Volume 10, Issue 2 (7-2022)                   J. Pediatr. Rev 2022, 10(2): 121-128 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tabrizi M, Hoseini Nouri S A, Zarkesh M, Hassanzadeh Rad A, Hashemi Dehkordi E, Dalili S. Management of Growth in Pediatric Chronic Renal Failure: A Narrative Review. J. Pediatr. Rev. 2022; 10 (2) :121-128
URL: http://jpr.mazums.ac.ir/article-1-445-en.html
1- Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
2- Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
3- Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. , setiladalili1346@yahoo.com
Abstract:   (1050 Views)
Background: Growth impairment is a common problem in Chronic Kidney Disease (CKD) children. Approximately 40% of children with CKD have a reduced final height. Growth impairment affects school attendance, duration of hospitalization, adult height, and even risk of death. 
Objectives: Various studies have shown that patients with moderate to severe growth failure have higher mortality rates (three folds) than those with normal growth. This narrative review aimed to define the management of growth in pediatric chronic renal failure.
Methods: This study was conducted through a literature search with the keywords of chronic renal failure, kidney transplant, Glomerular Filtration Rate (GFR) combined with growth, short stature, and growth hormone using PubMed, Scopus, Web of Sciences, Cochrane, and Embase databases.
Results: Growth impairment in children with CKD occurs due to diverse etiologies, such as uremia, anemia, metabolic acidosis, etc. It becomes more prominent in GFR<75 ml/min/1.73 m2. Growth hormone (GH) therapy seems to be a safe and effective therapeutic modality consequent to the correction of associated metabolic disturbances.
Conclusions: This study indicated that pretransplant GH therapy in children with CKD and its temporary discontinuation at kidney transplantation up to one year after transplantation leads to improved growth velocity. Therefore, it seems that considering GH therapy in children with CKD is mandatory.
Full-Text [PDF 425 kb]   (384 Downloads) |   |   Full-Text (HTML)  (21 Views)  
Type of Study: Narrative Review | Subject: Pediatric Endocrinology
Received: 2021/12/8 | Accepted: 2021/12/27 | Published: 2022/04/25

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Pediatrics Review

Designed & Developed by : Yektaweb